NAD+ 500 mg

Peptide Hubs NAD+ 500 mg

NAD+ 500 mg represents a high-concentration formulation of nicotinamide adenine dinucleotide, presented as 500 mg of lyophilized powder in a sterile 2 mL vial. This high-potency coenzyme formulation enables advanced research into cellular energy metabolism, aging mechanisms, and mitochondrial function at concentrations previously challenging to achieve in experimental settings. Independently verified at 529.56 mg content (105.9% purity), this pharmaceutical-grade NAD+ provides researchers with unprecedented dosing flexibility for investigations requiring substantial coenzyme delivery. Manufactured under exacting quality control standards, the 500 mg concentration addresses the growing research demand for higher NAD+ doses in studies exploring cellular resilience, metabolic regulation, and age-related decline reversal.

NAD+ 500 mg Chemical Composition

Each vial contains 500 mg of high-purity β-Nicotinamide Adenine Dinucleotide (oxidized form) with enhanced stability characteristics:

• Chemical Name: β-Nicotinamide Adenine Dinucleotide (oxidized form)
• Molecular Formula: C₂₁H₂₇N₇O₁₄P₂
• Molecular Weight: 663.43 g/mol
• CAS Number: 53-84-9
• Purity: >99% confirmed by reverse-phase HPLC and mass spectrometry
• Form: White crystalline lyophilized powder
• Concentration: 500 mg/vial (250 mg/mL when reconstituted with 2 mL)
• Stabilization: Contains excipients specifically selected for high-concentration NAD+ stabilization
• Redox State: Preserved oxidized (NAD+) form with minimal reduction during manufacturing

The high-concentration formulation maintains NAD+'s structural integrity while enabling research applications requiring substantial coenzyme delivery unavailable in standard 100 mg preparations.

Research Applications for High-Concentration NAD+

The 500 mg concentration enables advanced research previously limited by dosage constraints:

• High-Dose Metabolic Studies: Enables research exploring dose-response relationships at concentrations relevant to clinical translation, particularly in large animal models and chronic administration protocols.
• Chronic Aging Interventions: Supports long-term studies requiring sustained NAD+ elevation to investigate cumulative effects on aging biomarkers, tissue function, and lifespan extension.
• Tissue-Specific Research: Facilitates investigations into NAD+ distribution, tissue-specific accumulation, and organ-level metabolic effects that require higher systemic doses.
• Combination Therapy Research: Enables studies combining NAD+ with other compounds at ratios that maintain appropriate molar relationships in complex intervention protocols.
• Pharmacokinetic Investigations: Supports research on NAD+ absorption, distribution, metabolism, and excretion at doses that produce measurable tissue concentrations.
• Rescue Studies: Allows investigation of NAD+ administration in models of severe metabolic dysfunction or accelerated aging where higher doses may be necessary to produce observable effects.

Therapeutic Context for High-Dose NAD+

While this product is for research use only, scientific literature provides context for high-dose NAD+ applications. According to research published in Science, restoring NAD+ levels in aged mice improved mitochondrial function, enhanced muscle strength, and extended healthspan. The study utilized doses equivalent to approximately 400-500 mg/kg in mouse models, highlighting the need for higher concentrations in aging intervention research. Further investigation in Cell Metabolism demonstrated that NAD+ precursors at high doses could improve cognitive function and reduce neuroinflammation in Alzheimer's disease models. These studies underscore the importance of higher NAD+ concentrations for investigating age-related decline and metabolic disorders in research settings.

High-Concentration Protocols

Important: The following information is derived from published research and should only guide experimental design in appropriate research models. Always consult institutional protocols.

• Large Animal Research: For studies in larger species (dogs, primates), doses of 50-200 mg/kg may be required to achieve tissue concentrations comparable to effective doses in rodent studies.
• Chronic Administration Protocols: Long-term studies (weeks to months) may utilize 100-300 mg/kg daily, with adjustments based on species, age, and metabolic status of research models.
• Reconstitution for High Concentration: Add 2 mL of sterile phosphate-buffered saline (pH 7.4) to yield 250 mg/mL (250,000 mcg/mL). This high concentration may require gentle warming (37°C water bath) and extended mixing for complete dissolution.
• Administration Considerations: Due to the high concentration, careful injection technique is essential to prevent local irritation. Consider dividing doses or using slower infusion rates in sensitive models.
• Dose Escalation Protocols: When initiating high-dose studies, consider gradual dose escalation over 3-7 days to allow physiological adaptation and minimize potential adverse effects.
• Volume Adjustments: For species with smaller blood volumes, reconstitution with larger volumes (3-4 mL) may be necessary to achieve administrable injection volumes while maintaining appropriate concentrations.

Pharmacokinetics of High-Dose NAD+ Administration

High-dose NAD+ administration presents unique pharmacokinetic considerations:

• Absorption Saturation: At high doses, NAD+ absorption and cellular uptake mechanisms may approach saturation, altering linear pharmacokinetics observed at lower doses.
• Metabolic Conversion: High systemic NAD+ increases substrate availability for NAD+-consuming enzymes (PARPs, sirtuins, CD38), potentially accelerating conversion to metabolites.
• Tissue Accumulation: Prolonged high-dose administration may lead to tissue accumulation not observed with lower doses, particularly in metabolically active organs.
• Redox Balance Effects: Substantial NAD+ elevation can shift cellular redox balance, influencing NADH/NAD+ ratios and affecting metabolic flux through redox-sensitive pathways.
• Feedback Regulation: High doses may activate feedback mechanisms regulating NAD+ biosynthesis and degradation, necessitating careful monitoring in chronic studies.
• Excretion Patterns: Metabolite excretion patterns may differ at high doses, potentially affecting interpretation of pharmacokinetic data.

Potential Research Observations with High-Dose NAD+

Researchers should monitor for effects specific to high-concentration administration:

• Enhanced Metabolic Effects: More pronounced improvements in mitochondrial function, glucose metabolism, and energy expenditure compared to standard doses
• Accelerated Phenotypic Changes: More rapid manifestation of expected effects on aging markers, exercise performance, or cognitive function in appropriate models
• Dose-Dependent Responses: Clear dose-response relationships for parameters that may show threshold effects or saturation kinetics
• Tissue-Specific Effects: Differential responses across tissues based on NAD+ distribution and local metabolism
• Adaptive Responses: Potential upregulation of NAD+-consuming enzymes or compensatory changes in NAD+ biosynthesis pathways
• Local Reactions: Increased likelihood of injection site reactions due to high concentration and osmolarity
• Systemic Effects: More pronounced effects on blood pressure, heart rate, or other physiological parameters at very high doses

Safety Considerations

This high-concentration formulation requires additional safety considerations:

• Not for Human Use: This product is for laboratory research only and not for human or veterinary therapeutic use
• Concentration-Specific Protocols: Develop administration protocols specific to this high concentration, including appropriate dilution if necessary
• Injection Technique: Use proper technique to minimize local tissue irritation from high-concentration injections
• Metabolic Monitoring: Implement enhanced metabolic monitoring in studies using high doses, particularly glucose homeostasis and liver function
• Gradual Introduction: Consider dose escalation protocols rather than immediate high-dose administration
• Specialized Handling: Use appropriate personal protective equipment and work in certified laboratory facilities
• Enhanced Record Keeping: Maintain detailed records of reconstitution, administration, and observations specific to high-dose use
• Waste Disposal: Follow institutional protocols for chemical and biological waste disposal of high-concentration materials

Overdose Considerations

Administration significantly above established high-dose parameters may produce amplified effects including pronounced metabolic disturbances, potential electrolyte imbalances, or excessive redox state alterations that could compromise animal welfare. Researchers should implement comprehensive monitoring including metabolic panels, behavioral assessments, and physiological measurements. Emergency procedures should include capabilities for metabolic support, fluid administration, and intensive monitoring for research models receiving very high NAD+ doses.

NAD+ Research Combinations

The 500 mg concentration enables research combinations requiring substantial NAD+ co-administration:

• NAD+ 100 mg: For dose-response studies comparing different NAD+ concentrations on cellular, metabolic, and aging outcomes across a wide dose range.
• Epitalon 50 mg: In high-dose aging intervention research combining NAD+ restoration with telomerase activation pathways.
• GHK-Cu 50 mg: For studies on combined tissue repair, collagen synthesis, and cellular energy optimization in aging or injury models.
• PE 22-28: In metabolic syndrome research combining high-dose NAD+ with glucose-dependent insulinotropic peptide analogs.
• Adipotide (FTPP) 10 mg: For investigations of combined metabolic effects targeting both cellular energy pathways and adipose tissue biology.

These high-dose combinations should only be investigated by experienced researchers with appropriate infrastructure for comprehensive physiological monitoring and ethical oversight. Studies should include careful dose justification, escalation protocols, and contingency planning for potential amplified effects.

Package Presentation for High-Concentration NAD+

Each high-concentration unit features specialized packaging:

• One sterile amber glass vial with fluoropolymer-coated stopper containing 500 mg lyophilized NAD+
• Enhanced oxygen barrier packaging with dual oxygen-absorbing packets
• Desiccant canister for moisture control during shipping and storage
• Tamper-evident holographic security seal with batch-specific authentication
• Dual lot numbers, manufacture date, and extended expiration documentation
• Comprehensive certificate of analysis including stability data for high-concentration formulation
• Product insert with specific handling instructions for high-concentration NAD+
• Material Safety Data Sheet (MSDS) specific to concentrated NAD+ formulation
• Reconstitution guide addressing solubility considerations at high concentrations

Enhanced Storage Requirements for High-Concentration NAD+

The 500 mg concentration necessitates enhanced storage protocols:

• Primary Storage: Store at -20°C to -80°C (-4°F to -112°F) in original packaging. For active use, -20°C (-4°F) is minimum requirement.
• Transport Conditions: Ship and transport on dry ice or equivalent cold chain maintenance.
• Reconstituted Solution: Prepare immediately before use. Do not store reconstituted solution. If absolutely necessary, store at 2-8°C (36-46°F) for no more than 2 hours.
• Light Protection: Absolute light protection required. Use amber vials and work under yellow or red light when possible.
• Temperature Monitoring: Implement continuous temperature monitoring during storage with alarm capabilities.
• Stability Duration: Properly stored lyophilized powder maintains stability for 12 months. Monitor for color changes more frequently than with standard concentrations.
• Multiple Aliquot Consideration: If dividing into aliquots, use sterile technique and maintain cold chain throughout process.
• Freeze-Thaw Cycles: Avoid freeze-thaw cycles. Store in single-use aliquots if repeated use is anticipated.

High-Concentration NAD+ Research Significance

The development of a stable 500 mg NAD+ formulation represents a significant advancement for aging, metabolism, and mitochondrial research. As detailed in expanding scientific literature, effective NAD+ restoration in age-related decline and metabolic disorders often requires doses exceeding those achievable with standard preparations. The January 15, 2026 laboratory verification showing 529.56 mg content (105.9% purity) in the 500 mg vial demonstrates exceptional manufacturing precision for this challenging high-concentration formulation. This advancement enables researchers to explore dose ranges relevant to translational applications, investigate saturation kinetics of NAD+-dependent pathways, and conduct long-term intervention studies without frequent reconstitution. The preserved oxidized redox state ensures compatibility with research on sirtuin activation, PARP-mediated DNA repair, and cellular signaling—processes specifically dependent on NAD+ rather than its reduced form. By providing this high-concentration option alongside standard 100 mg preparations, Peptide Hubs supports comprehensive research spanning from mechanistic studies to intervention protocols with potential translational relevance.

Third-Party Laboratory Verification

January 15, 2026

View Result

529.56 mg / 500 mg

The independent laboratory analysis conducted on January 15, 2026, confirms the high-concentration NAD+ vial contains 529.56 mg of active content against the labeled 500 mg, representing a 105.9% purity rating that demonstrates exceptional manufacturing precision for this challenging formulation. This verification ensures researchers receive accurately dosed high-concentration materials for advanced investigations into cellular energy metabolism, aging interventions, and metabolic regulation requiring substantial NAD+ delivery.